Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers

Core Insights - Microbot Medical Inc. has strengthened its U.S. commercial leadership team with the addition of a new Vice President of Marketing and a Director of Human Resources, preparing for the launch of its LIBERTY® Endovascular Robotic System [1][4][6] - Positive data from a pivotal study has increased confidence in the market reception of LIBERTY® [1] Leadership Additions - Allison Rosefort has been appointed as Vice President of Marketing, bringing over 15 years of experience in healthcare marketing and a proven track record of driving double-digit revenue growth [2][3] - Lisa Dobbins has joined as Director of Human Resources, with a background in building high-performing teams in the MedTech sector [4][5] Commercialization Strategy - The company aims to be ready for the immediate launch of LIBERTY® following FDA clearance, reflecting its commitment to establishing a robust commercial infrastructure [6] - The recent hiring of Paul Mullen as Vice President of Sales complements the new marketing and HR leadership, enhancing the company's commercialization readiness [1][6] Product Overview - LIBERTY® is an investigational device pending FDA 510(k) clearance and is not currently available for sale in the U.S. [6] - The device is designed to redefine endovascular robotics and improve patient care globally [7]